{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T18:37:28Z","timestamp":1791225448914,"version":"4.1.0"},"reference-count":38,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","license":[{"start":{"date-parts":[[2011,4,1]],"date-time":"2011-04-01T00:00:00Z","timestamp":1301616000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,4]]},"DOI":"10.1038\/ajg.2011.70","type":"journal-article","created":{"date-parts":[[2011,3,15]],"date-time":"2011-03-15T11:40:38Z","timestamp":1300189238000},"page":"590-599","source":"Crossref","is-referenced-by-count":279,"title":["Glucocorticosteroid Therapy in Inflammatory Bowel Disease: Systematic Review and Meta-Analysis"],"prefix":"10.14309","volume":"106","author":[{"given":"Alexander C","family":"Ford","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles N","family":"Bernstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khurram J","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria T","family":"Abreu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John K","family":"Marshall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas J","family":"Talley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Moayyedi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-6-20210306","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1002\/ibd.20029","article-title":"Update on the incidence and prevalence of Crohns disease and ulcerative colitis in Olmsted County, Minnesota, 1940-2000.","volume":"13","author":"Loftus","year":"2007","journal-title":"Inflamm Bowel Dis"},{"key":"R2-6-20210306","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1016\/j.cgh.2007.07.012","article-title":"The prevalence and geographic distribution of Crohns disease and ulcerative colitis in the United States.","volume":"5","author":"Kappelman","year":"2007","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R3-6-20210306","first-page":"1161","article-title":"Crohns disease in Olmsted County, Minnesota, 1940-1993: incidence, prevalence, and survival.","volume":"116","author":"Loftus","year":"1999","journal-title":"Gastroenterology"},{"key":"R4-6-20210306","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1136\/gut.46.3.336","article-title":"Ulcerative colitis in Olmsted County, Minnesota, 1940-1993: incidence, prevalence, and survival.","volume":"46","author":"Loftus","year":"2000","journal-title":"Gut"},{"key":"R5-6-20210306","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/S0025-6196(24)00526-3","article-title":"The effects of the adrenal cortical hormone 17-hydroxy-11-dehydrocorticosterone (Compound E) on the acute phase of rheumatic fever; preliminary report.","volume":"24","author":"Hench","year":"1949","journal-title":"Mayo Clin Proc"},{"key":"R6-6-20210306","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1136\/bmj.2.4884.375","article-title":"Cortisone in ulcerative colitis; preliminary report on a therapeutic trial.","volume":"2","author":"Truelove","year":"1954","journal-title":"BMJ"},{"key":"R7-6-20210306","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.ejphar.2004.07.011","article-title":"Effects of glucocorticoids on gene transcription.","volume":"500","author":"Hayashi","year":"2004","journal-title":"Eur J Pharmacol"},{"key":"R8-6-20210306","doi-asserted-by":"crossref","first-page":"2524","DOI":"10.1038\/ajg.2009.322","article-title":"Adverse events associated with common therapy regimens for moderate-to-severe Crohns disease.","volume":"104","author":"Marehbian","year":"2009","journal-title":"Am J Gastroenterol"},{"key":"R9-6-20210306","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1007\/BF00609625","article-title":"Topical and systemic glucocorticoid potencies of budesonide and belcomethasone dipropionate in man.","volume":"22","author":"Johansson","year":"1982","journal-title":"Eur J Clin Pharmacol"},{"key":"R12-6-20210306","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1046\/j.1365-2036.2002.01289.x","article-title":"The effectiveness of budesonide therapy for Crohns disease.","volume":"16","author":"Kane","year":"2002","journal-title":"Aliment Pharmacol Ther"},{"key":"R13-6-20210306","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/S0025-7753(01)71716-2","article-title":"Budesonide in inflammatory bowel disease: a meta-analysis.","volume":"116","author":"Nos","year":"2001","journal-title":"Med Clin (Barc)"},{"key":"R14-6-20210306","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1046\/j.1365-2036.2000.00867.x","article-title":"Budesonide in the treatment of Crohns disease: a meta-analysis.","volume":"14","author":"Papi","year":"2000","journal-title":"Aliment Pharmacol Ther"},{"key":"R17-6-20210306","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials.","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Control Clin Trials"},{"key":"R18-6-20210306","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses.","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"R19-6-20210306","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test.","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"key":"R20-6-20210306","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/0016-5085(84)90409-8","article-title":"European cooperative Crohns disease study (ECCDS): results of drug treatment.","volume":"86","author":"Malchow","year":"1984","journal-title":"Gastroenterology"},{"key":"R21-6-20210306","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/0016-5085(79)90385-8","article-title":"National cooperative Crohns disease study (ECCDS): results of drug treatment.","volume":"77","author":"Summers","year":"1979","journal-title":"Gastroenterology"},{"key":"R22-6-20210306","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1056\/NEJM199409293311303","article-title":"Oral budesonide for active Crohns disease.","volume":"331","author":"Greenberg","year":"1994","journal-title":"N Engl J Med"},{"key":"R23-6-20210306","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1111\/j.1572-0241.2002.05835.x","article-title":"Budesonide CIR capsules (once or twice daily divided-dose) in active Crohns disease: a randomized placebo-controlled study in the United States.","volume":"97","author":"Tremaine","year":"2002","journal-title":"Am J Gastroenterol"},{"key":"R24-6-20210306","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/S0016-5085(98)70254-9","article-title":"Budesonide versus prednisone in the treatment of active Crohns disease.","volume":"115","author":"Bar-Meir","year":"1998","journal-title":"Gastroenterology"},{"key":"R25-6-20210306","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1136\/gut.41.2.209","article-title":"Oral budesonide is as effective as oral prednisolone in active Crohns disease.","volume":"41","author":"Campieri","year":"1997","journal-title":"Gut"},{"key":"R26-6-20210306","first-page":"905","article-title":"Oral pH-modified release budesonide versus 6-methylprednisolone in active Crohns disease.","volume":"8","author":"Gross","year":"1996","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"R27-6-20210306","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1056\/NEJM199409293311304","article-title":"A comparison of budesonide with prednisolone for active Crohns disease.","volume":"331","author":"Rutgeerts","year":"1994","journal-title":"N Engl J Med"},{"key":"R28-6-20210306","first-page":"129","article-title":"Beclomethasone dipropionate for the treatment of mild-to-moderate Crohns disease: an open-label, budesonide-controlled, randomized study.","volume":"12","author":"Tursi","year":"2006","journal-title":"Med Sci Monit"},{"key":"R29-6-20210306","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1111\/j.1365-2036.1995.tb00367.x","article-title":"Budesonide and prednisolone suppress peripheral blood natural killer cells in Crohns disease.","volume":"9","author":"Van Ierrsel","year":"1995","journal-title":"Aliment Pharmacol Ther"},{"key":"R30-6-20210306","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1136\/gut.1.3.217","article-title":"An assessment of prednisone, salazopyrin, and topical hydrocortisone hemisuccinate used as out-patient treatment for ulcerative colitis.","volume":"1","author":"Lennard-Jones","year":"1960","journal-title":"Gut"},{"key":"R31-6-20210306","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1136\/bmj.2.4947.1041","article-title":"Cortisone in ulcerative colitis: final report on a therapeutic trial.","volume":"2","author":"Truelove","year":"1955","journal-title":"BMJ"},{"key":"R32-6-20210306","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1136\/gut.33.5.711","article-title":"Oral fluticasone propionate in active distal ulcerative colitis.","volume":"33","author":"Angus","year":"1992","journal-title":"Gut"},{"key":"R33-6-20210306","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1046\/j.1365-2036.2002.01298.x","article-title":"Oral beclometasone dipropionate in the treatment of active ulcerative colitis: a double-blind placebo-controlled study.","volume":"16","author":"Rizzello","year":"2002","journal-title":"Aliment Pharmacol Ther"},{"key":"R34-6-20210306","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1111\/j.1572-0241.2008.02103.x","article-title":"Erythrocyte-mediated delivery of dexamethasone in patients with mild-to-moderate ulcerative colitis, refractory to mesalamine: a randomized, controlled study.","volume":"103","author":"Bossa","year":"2008","journal-title":"Am J Gastroenterol"},{"key":"R35-6-20210306","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1053\/gast.1996.v110.pm8536887","article-title":"Oral budesonide as maintenance treatment for Crohns disease: a placebo-controlled, dose-ranging study.","volume":"110","author":"Greenberg","year":"1996","journal-title":"Gastroenterology"},{"key":"R36-6-20210306","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1136\/gut.39.1.82","article-title":"Budesonide prolongs time to relapse in ileal and ileocaecal Crohns disease. A placebo controlled one year study.","volume":"39","author":"Lofberg","year":"1996","journal-title":"Gut"},{"key":"R37-6-20210306","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1046\/j.1365-2036.1998.00285.x","article-title":"Oral budesonide as maintenance therapy in Crohns diseaseresults of a 12-month study.","volume":"12","author":"Ferguson","year":"1998","journal-title":"Aliment Pharmacol Ther"},{"key":"R38-6-20210306","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1136\/gut.42.4.493","article-title":"Low dose oral pH modified release budesonide for maintenance of steroid induced remission in Crohns disease.","volume":"42","author":"Gross","year":"1998","journal-title":"Gut"},{"key":"R39-6-20210306","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1111\/j.1365-2036.2005.02338.x","article-title":"Budesonide as maintenance treatment in Crohns disease: a placebo-controlled trial.","volume":"21","author":"Hanauer","year":"2005","journal-title":"Aliment Pharmacol Ther"},{"key":"R40-6-20210306","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1136\/gut.48.2.186","article-title":"Switch from systemic corticosteroids to budesonide in steroid dependent patients with inactive Crohns disease.","volume":"48","author":"Cortot","year":"2001","journal-title":"Gut"},{"key":"R41-6-20210306","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1136\/bmj.323.7303.42","article-title":"Assessing the quality of controlled clinical trials.","volume":"323","author":"Juni","year":"2001","journal-title":"BMJ"},{"key":"R42-6-20210306","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.cgh.2006.09.033","article-title":"Response to corticosteroids in severe ulcerative colitis: a systematic review of the literature and a meta-regression.","volume":"5","author":"Turner","year":"2007","journal-title":"Clin Gastroenterol Hepatol"}],"container-title":["American Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/ajg201170.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/ajg201170","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/ajg201170.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/www.ovid.com\/00000434-201104000-00006","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T14:13:52Z","timestamp":1786544032000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00000434-201104000-00006"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,4]]},"references-count":38,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2011]]}},"URL":"https:\/\/doi.org\/10.1038\/ajg.2011.70","relation":{},"ISSN":["0002-9270"],"issn-type":[{"value":"0002-9270","type":"print"}],"subject":[],"published":{"date-parts":[[2011,4]]}}}